Clinical trials: Rectal Tumors
Advanced Solid Tumor, Non-Small Cell Lung Cancer
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or…
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07629960
- Testing
- BLU-924
- Where
- 16 sites in United States, Spain
- Volunteers
- 265 people
- Sponsor
- Blueprint Medicines Corporation
Colorectal Cancer
Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00112918
- Testing
- Bevacizumab, Capecitabine, 5-Fluorouracil (5-FU)
- Where
- United States
- Volunteers
- 3,451 people
- Sponsor
- Hoffmann-La Roche
Gastric Cancer, Colorectal Cancer
A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors
This is a single arm, open-label, dose escalation, PK expansion and efficacy expansion study of phase I. The purpose of this study is to assess the tolerability, safety, pharmacokinetics and immunogenicity of SHR-A1811 and…
- Trial name
- NCT04513223
- Testing
- SHR-A1811
- Where
- China
- Volunteers
- 101 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Colorectal Neoplasms
Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer
Study to evaluate the anti-tumour activity, safety and pharmacokinetics of unlabelled sibrotuzumab administered weekly (seven days +/- one day) at a dose of 100 mg (a total of 12 administrations) in patients with metastatic…
- Trial name
- NCT02198274
- Testing
- BIBH 1
- Volunteers
- 25 people
- Sponsor
- Boehringer Ingelheim
Metastatic Colorectal Cancer
A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer
This is an open-label, multicenter, phase 1 study of BBI608 in combination with FOLFIRI + Bavacizumab. This study population is adult Japanese patients with metastatic colorectal cancers in FOLFIRI + Bevacizumab combination…
- Trial name
- NCT02641873
- Testing
- BBI608, 5-FU, Irinotecan
- Where
- 2 sites in Japan
- Volunteers
- 4 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Locally Advanced Rectal Cancer
Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer
The main purpose of the study was to define maximum tolerated dose (MTD), recommended Phase II dose (RP2D) safety and tolerability of Peposertib in combination with capecitabine and radiotherapy (RT).
- Trial name
- NCT03770689
- Testing
- Peposertib 50 mg, Peposertib 100 mg, Peposertib 150 mg
- Where
- 14 sites in United States, Spain
- Volunteers
- 19 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Neoplasms, Rectal
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
The purpose of this study is to investigate dostarlimab monotherapy in participants with locally advanced Mismatch-repair deficient (dMMR)/Microsatellite instability-high (MSI-H) rectal cancer who have received no prior…
- Trial name
- AZUR-1 (NCT05723562)
- Testing
- Dostarlimab
- Where
- 42 sites in United States, Canada and 8 more
- Volunteers
- 154 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumors, Advanced or Metastatic Biliary Cancer
A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer
This is a Phase 1 study during which patients with advanced solid tumors will receive investigational study drug ARRY-438162 (MEK162). This study has 3 parts.
- Conditions
- Advanced Solid Tumors, Advanced or Metastatic Biliary Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT00959127
- Testing
- ARRY-438162 (MEK162), MEK inhibitor; oral
- Where
- 10 sites in United States
- Volunteers
- 93 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Metastatic Colorectal Cancer (mCRC)
Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients
This is a multicenter, open label, randomized bioequivalence study of BEVZ92 (bevacizumab biosimilar) and Avastin® with 2 parallel arms to compare the pharmacokinetic (PK) profile of BEVZ92 and Avastin® in combination with FOLFOX…
- Trial name
- NCT02069704
- Testing
- Bevacizumab biosimilar (BEVZ92), Avastin® (bevacizumab, reference product)
- Where
- 18 sites in Argentina, Brazil and 3 more
- Volunteers
- 142 people
- Sponsor
- mAbxience Research S.L.
Colorectal Cancer
A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
This Phase II, multicenter, double-blind, randomized, active-controlled trial is designed to evaluate the efficacy and safety of rhuMAb VEGF (Avastin) when administered at a dose of 5 mg/kg every 2 weeks in combination with 5 FU…
- Trial name
- NCT00109226
- Testing
- Avastin (Bevacizumab)
- Sponsor
- Genentech, Inc.
Solid Tumor, Adult, Bladder Cancer
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
This is an open-label pilot study of a new PET/CT imaging agent MNPR-101-DFO*-89Zr in patients with solid tumor cancers. These cancers may include bladder/urothelial, triple-negative breast, lung, colorectal, gastric, ovarian…
- Conditions
- Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer
- Trial name
- NCT06337084
- Testing
- MNPR-101-DFO*-89Zr, PET/CT Diagnostic Imaging
- Where
- Australia
- Volunteers
- 12 people
- Sponsor
- Monopar Therapeutics
Metastatic Colorectal Cancer
A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer.
This study aims to comprehensively identify the various treatment patterns of second- or subsequent-line palliative chemotherapy used in patients with metastatic colorectal cancer who have experienced failure of first-line…
- Trial name
- NCT07263178
- Testing
- Second and later-line palliative chemotherapy
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Colonic Polyp, Colon Adenoma
Feasibility Study of a Novel Single Use Robotic Colonoscopy System
This is a single centre, non-randomized, tandem colonoscopy trial of the NISInspire-C System, followed immediately by a conventional colonoscope (CC).
- Conditions
- Colonic Polyp, Colon Adenoma, Colorectal Cancer
- Trial name
- NCT03979690
- Testing
- NISInspire-C System
- Where
- Hong Kong
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bio-Medical Engineering (HK) Limited
Colorectal Cancer, Adenomatous Polyp of Colon
CRC Screening Using mSEPT9 (Methylated Septin 9) in Chinese Population
The purpose of this study is to evaluate the performance of the SEPT9 gene methylation assay in Colorectal cancer (CRC) high-risk population in Chinese hospitals using the opportunistic screening method.
- Conditions
- Colorectal Cancer, Adenomatous Polyp of Colon, Polyps, Other Disease/Injury
- Trial name
- RESEPT (NCT02540850)
- Where
- 4 sites in China
- Volunteers
- 1,031 people, healthy volunteers welcome
- Sponsor
- BioChain (Beijing) Science and Technology, Inc.
Colorectal Cancer
An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer
This prospective observational study will evaluate the efficacy and safety of bevacizumab in combination with capecitabine and oxaliplatin as first-line treatment in participants with colorectal cancer.
- Trial name
- NCT01399190
- Testing
- Bevacizumab, Capecitabine, Oxaliplatin
- Where
- 9 sites in Slovakia
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer.
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06704724
- Testing
- PF-07985045, Gemcitabine, Nab-paclitaxel
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 30 people
- Sponsor
- Pfizer
Advanced Cancer, Metastatic Cancer
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART0380 that can be given safely to participants…
- Conditions
- Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04657068
- Testing
- ART0380, Gemcitabine, Irinotecan
- Where
- 88 sites in United States, France and 2 more
- Volunteers
- 542 people
- Sponsor
- Artios Pharma Ltd
Metastatic Colorectal Cancer
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
This study includes two parts:Part 1: SSGJ-707 (different dosing regimens) in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.Part 2: SSGJ-707 in combination with chemotherapy versus…
- Trial name
- NCT06493760
- Testing
- SSGJ-707, Bevacizumab, Oxaliplatin
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Metastatic Colorectal Cancer
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
This is a Phase 2, multicenter, multiple-arm, open-label study to evaluate the efficacy, safety, and tolerability of EZN-2208. EZN-2208 will be administered as a single agent in patients with K-RAS mutations in the tumors.
- Trial name
- NCT00931840
- Testing
- EZN-2208, Cetuximab and Irinotecan
- Where
- 60 sites in United States, Canada and 3 more
- Volunteers
- 220 people
- Sponsor
- Enzon Pharmaceuticals, Inc.
Cancer
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
This was a four part, phase I/II study aimed to evaluate the safety, tolerability and efficacy of combination of an anti-EGFR antibody panitumumab (P) either with a BRAF inhibitor (dabrafenib (D); GSK2118436) alone or with the…
- Trial name
- NCT01750918
- Testing
- Dabrafenib, Trametinib, Panitumumab
- Where
- 20 sites in United States, Belgium and 6 more
- Volunteers
- 166 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.